Detailed Safety Review of
Anthrax Vaccine Adsorbed – January 2015.
Compiled by the Immunization Healthcare Branch Defense Health Agency, Falls Church, Virginia).
Link to report
– updated July 2012 [link].
1) reducing the number of doses required to complete the
pre-event and preexposure primary series from 6 doses to
2) recommending intramuscular rather than subcutaneous
AVA administration for preexposure use,
3) recommending AVA as a component of postexposure
prophylaxis in pregnant women exposed to aerosolized
Bacillus anthracis spores,
4) providing guidance regarding preexposure vaccination
of emergency and other responder organizations under the
direction of an occupational health program, and
5) recommending 60 days of antimicrobial prophylaxis in
conjunction with 3 doses of AVA for optimal protection
of previously unvaccinated persons after exposure to
aerosolized B. anthracis spores.
CDC’s Vaccine Information
Statement (VIS) updated March 2010 [link]
Stewart B, et al.
Health-related quality of life in the CDC
Anthrax Vaccine Adsorbed Human Clinical Trial.
A study of more than 1500 participants
found no association between receipt of Anthrax Vaccine
and altered health-related quality of life over 3.5
Murphy D, et al.
A longitudinal study of UK military personnel
offered anthrax vaccination: informed choice, symptom
reporting, uptake and pre-vaccination health.
UK service personnel were followed for
3-6 years after anthrax vaccination to assess long term
health. Anthrax vaccination was not associated with
long term adverse health problems. However, symptoms
were associated with making an uninformed choice to
undergo the vaccination. The results are important both
for the safety of the vaccine and for future policies
should anthrax vaccination be required in either
military or non military populations.
US Department of Defense announced the continuation
of the mandatory Anthrax Vaccine Immunization Program "for military personnel, emergency-essential DoD civilians and contractors, based on defined geographic areas or roles". (News
Release Oct 16 2006)
The Anthrax Vaccine: Is It Safe? Does It Work?
reports the study’s conclusion that the vaccine is
acceptably safe and effective in protecting humans
against anthrax. The book also includes a description of
advances needed in main areas: improving the way the
vaccine is now used, expanding surveillance efforts to
detect side effects from its use, and developing a
better vaccine. (March 6, 2002).
for Health Security (formerly the Center
for Biosecurity of UPMC) at the
University of Pittsburgh Medical Center -
As of November 1,
2003, the faculty and staff formerly of the
Johns Hopkins Center for Civilian Biodefense Strategies
are now affiliated with the Center for
Biosecurity of the University of Pittsburgh Medical
Center (UPMC) located in Baltimore, MD.
Centers for Disease Control and Prevention
U.S. Department of
World Health Organization